Limited Time Offer. Become a Founder Member Now!

Commission highlights new Massachusetts drug-price law and its implications for residents with disabilities

January 15, 2025 | Revere City, Suffolk County, Massachusetts


This article was created by AI summarizing key points discussed. AI makes mistakes, so for full details and context, please refer to the video of the full meeting. Please report any errors so we can fix them. Report an error »

Commission highlights new Massachusetts drug-price law and its implications for residents with disabilities
Commission members briefed the group on recent state legislation intended to make prescription drugs more affordable and explained how the law could affect residents with disabilities who rely on ongoing medication.

A member reported that Governor Maura Healey signed S.3012, described in the meeting as “an act that the pharmaceuticals access, cost and transparency,” and summarized key provisions the coalition highlighted: capped copays for certain chronic-condition medications (the meeting listed diabetes, asthma and prevalent heart conditions) with generic options available at no cost in some cases; expanded oversight and data collection by the Health Policy Commission (HPC) and the Center for Health Information and Analysis (CHIA); licensing and greater regulation of pharmacy benefits managers (PBMs); and a requirement that pharmacies present patients with the lowest-cost option available.

The presenter said the law was praised by disability advocates but noted it did not include every measure the coalition sought, such as mandatory HPC reviews of all drug-class impacts or including certain devices — cited in the meeting as insulin pumps — in copay caps.

One member asked whether the law included an effective date; the presenter said the material they shared only noted the bill’s signature and did not list an implementation date. Members recommended constituents and service users consult the bill text and official state sources for details on implementation timing and covered products.

No commission action was taken; the discussion served to inform members and constituents about potential cost reductions and continuing advocacy needs.

View full meeting

This article is based on a recent meeting—watch the full video and explore the complete transcript for deeper insights into the discussion.

View full meeting

Sponsors

Proudly supported by sponsors who keep Massachusetts articles free in 2025

Scribe from Workplace AI
Scribe from Workplace AI